Tong Sun, MD, PhD
Assistant Professor of PathologyCards
About
Titles
Assistant Professor of Pathology
Biography
Dr. Sun received her medical degree from Peking University Health Science center and her Ph.D. in molecular oncology from Peking Union Medical College. She joined in Gelb Genitourinary translation research center as a research fellow in Dana-Farber Cancer Institute/Harvard Medical School, where she was later promoted as a research scientist and mainly focused on genetic markers and post-translational regulation mechanism involved in castration resist prostate cancer. She completed residency training in Anatomic and Clinical Pathology at University of Massachusetts Medical School and a Cytopathology Fellowship at the Massachusetts General Hospital. She joined Yale Pathology Staff in 2020. Dr. Sun loves all aspects of general surgical pathology and cytopathology, but has research interests particularly in translational and molecular studies involving gynecological and gentiourinary pathology. She earned Warren R. Lang, MD Resident Physician Award and Journal of American Society of Cytopathology Physician-in-training Award for investigating utility of next-generation sequencing in urine cytology specimens. She has published more than 50 peer-reviewed publications including 5 book chapters and reviews. She serves as a reviewer for 25 scientific journals.
Last Updated on November 28, 2022.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Cytopathology Fellow
- Massachusetts General Hospital (2020)
- Resident Physcian
- University of Massachusetts (2019)
- Research Scientist
- Dana-Farber Cancer Institute (2015)
- Postdoctoral Research Fellow
- Dana-Farber Cancer Institute (2011)
- PhD
- Peking Union Medical College (2007)
- MD
- Peking University (2002)
Research
Publications
2025
Endometrial Carcinomas – Challenges and Updates on Selected Topics
Buza N, Sun T, Hui P. Endometrial Carcinomas – Challenges and Updates on Selected Topics. Human Pathology 2025, 106016. PMID: 41389900, DOI: 10.1016/j.humpath.2025.106016.Peer-Reviewed Original ResearchPrimary endometrial squamous cell carcinomaMinimal uterine serous carcinomaMesonephric-like adenocarcinomaEndometrial serous carcinomaSerous carcinomaEndometrial carcinomaEndometrioid carcinomaEndometrial squamous cell carcinomaVariant of endometrioid carcinomaSerous endometrial intraepithelial carcinomaHigh-grade endometrial carcinomasHeterogeneous group of tumorsSubtypes of endometrial carcinomaEndometrial cancer deathsHyalinized endometrioid carcinomaMinimal tumour volumeSuperficial serous carcinomaEndometrial intraepithelial carcinomaUterine serous carcinomaHeterogeneous groupAssociated with p53 abnormalitiesGroup of tumorsSquamous cell carcinomaExtrauterine spreadIntraepithelial carcinomaPrognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute
Wang M, Abi‐Raad R, Adeniran A, Krishnamurti U, Buza N, Hui P, Cai G, Sun T. Prognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute. Cancer Cytopathology 2025, 133: e70057. PMID: 41159755, DOI: 10.1002/cncy.70057.Peer-Reviewed Original ResearchConceptsEarly stage endometrial cancerPW cytologyStage endometrial cancerPelvic washingsAccurate risk stratificationEndometrial cancerPrognostic significancePrognostic impactIndependent predictorsInternational Federation of Gynecology and Obstetrics (FIGO) criteriaStage I/II endometrial cancerAccurate risk stratification of patientsIndependent adverse prognostic factorAssociated with significantly worse disease-free survivalRisk stratification of patientsPelvic washing cytologyRetrospective case-control cohortsMultivariate logistic regression analysisEndometrial cancer stagingAdverse prognostic factorDisease-free survivalInternational FederationTumor histologic subtypeII endometrial cancerEarly stage diseaseFumarate Hydratase-deficient Uterine Smooth Muscle Tumors: A 6-Year Prospective Analysis of Morphology-based Screening and Patient Outcomes.
Sun T, Niu N, Healy C, Abdelal H, Wang M, Hui P, Buza N. Fumarate Hydratase-deficient Uterine Smooth Muscle Tumors: A 6-Year Prospective Analysis of Morphology-based Screening and Patient Outcomes. International Journal Of Gynecological Pathology 2025 PMID: 40991420, DOI: 10.1097/pgp.0000000000001134.Peer-Reviewed Original ResearchUterine smooth muscle tumorsSmooth muscle tumorsFH deficiencyRenal cell carcinomaMuscle tumorsUterine leiomyomaCell carcinomaFumarate hydratasePathogenic variantsEarly-onset uterine leiomyomasGenetic counselingPapillary renal cell carcinomaProspective analysisFH-deficient leiomyomasGermline fumarate hydrataseSeventy-one tumorsAbnormal vaginal bleedingMedian patient ageHereditary cancer-related genesGermline pathogenic mutationsAutosomal dominant disorderFH-deficient tumorsCancer-related genesFH immunohistochemistryPelvic painHuman papillomavirus genotype distribution and its correlation with intraepithelial neoplasia, vaccination, and ethnicity
Abi-Raad R, Sun T, Krishnamurti U. Human papillomavirus genotype distribution and its correlation with intraepithelial neoplasia, vaccination, and ethnicity. Journal Of The American Society Of Cytopathology 2025, 14: 273-278. PMID: 40307088, DOI: 10.1016/j.jasc.2025.03.006.Peer-Reviewed Original ResearchConceptsHigh-risk human papillomavirusNon-16/18ASC-HHPV genotypesIntraepithelial neoplasiaCases of high-grade squamous intraepithelial lesionCervical cancerPositive high-risk HPVHigh-risk HPVHigh-risk human papillomavirus genotypesHuman papillomavirus genotype distributionNon-16/18 HPV genotypesPrevalence of HPV genotypesHigh-risk human papillomavirus typesHigh-grade intraepithelial neoplasiaIntroduction of HPV vaccinationIncidence of cervical cancerAtypical squamous cellsSquamous intraepithelial lesionsHigh-grade lesionsHSIL patientsNonvaccinated womenIntraepithelial lesionsVaccinated womenSquamous cells1035 Pathological and Molecular Signatures of De-differentiated Endometrial Carcinomas- An Institutional Study of 52 Cases
Arbelaez C, Babb P, Sun T, Buza N, Hui P. 1035 Pathological and Molecular Signatures of De-differentiated Endometrial Carcinomas- An Institutional Study of 52 Cases. Laboratory Investigation 2025, 105: 103269. DOI: 10.1016/j.labinv.2024.103269.Peer-Reviewed Original Research1044 Discordant HER2 Scores in Endometrial Cancer Using Endometrial versus Gastric Criteria: Implications for treatment eligibility
Moscona A, Babb P, Rottmann D, Sun T, Hui P, Buza N. 1044 Discordant HER2 Scores in Endometrial Cancer Using Endometrial versus Gastric Criteria: Implications for treatment eligibility. Laboratory Investigation 2025, 105: 103278. DOI: 10.1016/j.labinv.2024.103278.Peer-Reviewed Original Research340 Cytomorphologic Challenges in Cervical Pap Tests of Transgender Men on Androgen Therapy: A Cyto-Histological Correlation Study
Haque M, Amraei R, Iyer K, Krishnamurti U, Adeniran A, Sun T. 340 Cytomorphologic Challenges in Cervical Pap Tests of Transgender Men on Androgen Therapy: A Cyto-Histological Correlation Study. Laboratory Investigation 2025, 105: 102567. DOI: 10.1016/j.labinv.2024.102567.Peer-Reviewed Original Research315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration
Bernhisel A, Sun T, Prasad M, Ladenheim A, Cai G, Adeniran A. 315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration. Laboratory Investigation 2025, 105: 102542. DOI: 10.1016/j.labinv.2024.102542.Peer-Reviewed Original Research401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort Study
Wang M, Abi-Raad R, Krishnamurti U, Cai G, Adeniran A, Sun T. 401 Prognostic Value of Pelvic Washing Cytology in Early-Stage Endometrial Cancer: A 10-Year Single-Institute Cohort Study. Laboratory Investigation 2025, 105: 102628. DOI: 10.1016/j.labinv.2024.102628.Peer-Reviewed Original ResearchComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic target
News
News
Get In Touch
Contacts
Email